

氏名 清水 保明 (SHIMIZU Yasuaki)

所属 薬学部薬学科

職種 教授

生年月日 1955年9月15日

[履 歴]

[学 歴]

- 1978年3月 北海道大学薬学部製薬学科卒業
- 1980年3月 北海道大学大学院薬学研究科修士課程卒業
- 1984年3月 札幌医科大学大学院医学研究科博士課程卒業

[学 位]

医学博士

[職 歴]

- 1984年4月 山之内製薬 中央研究所分子生物学研究部 研究員
- 1999年8月 山之内製薬 創薬研究本部薬理第三研究室 室長
- 2005年4月 アステラス製薬 研究本部炎症研究室 室長
- 2009年4月 アステラス製薬 疼痛研究室 室長
- 2015年4月 アステラス製薬 再生医療研究所 次長
- 2017年3月 アステラス製薬 退社
- 2017年4月 青森大学 薬学部 教授

[教育活動]

[担当科目]

創薬学概論、化学療法学、微生物学、地域と健康、衛生学実習、薬学総合演習 I、薬学総合演習 II

[卒業研究指導]

2017年4月着任。2名の学生の卒業研究の指導開始。
有効な治療薬がない疾患を選択し、新規治療薬の創製方法を検討する。

[教育指導に関する特記事項]

- ・ 疾病の原因、自然経過及びそれに伴う病態変化の理解をベースに患者様の状態に合った最適の薬剤を助言出来る薬剤師の育成を目指す。
- ・ 知識が断片的にならないよう、正常（生理）－病気（病態生理）－薬理が繋がって

理解出来るよう教育する。

- ・ 学生が合点出来る、腑に落ちる、平易な説明を行う。

[研究活動]

[研究テーマ]

創薬研究の生産性向上のための仕組みづくり

[著書、論文、総説]

- 1) Ishikawa G, Nagakura Y, Takeshita N, Shimizu Y.: Efficacy of drugs with different mechanisms of action in relieving spontaneous pain at rest and during movement in a rat model of osteoarthritis. *Eur J Pharmacol.* 2014, 738:111-7.
- 2) Tasaki M, Kobayashi M, Tenda Y, Tsujimoto S, Nakazato S, Numazaki M, Hirano Y, Matsuda H, Terasaka T, Miyao Y, Shimizu Y, and Hirayama Y.: Inhibition of antigen-induced airway inflammation and hyperresponsiveness in guinea pigs by a selective antagonist of "chemoattractant receptor homologous molecule expressed on Th2 cells" (CRTH2). *Eur J Pharm Sci.* 2013, 49 (3): 434-440.
- 3) Systemic administration of 5-HT_{2C} receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Ogino S, Nagakura Y, Tsukamoto M, Watabiki T, Ozawa T, Oe T, Shimizu Y, and Ito H.: *Pharmacol Biochem Behav.* 2013, 108: 8-15
- 4) Automated measurement of spontaneous pain-associated limb movement and drug efficacy evaluation in a rat model of neuropathic pain. Kawasaki-Yatsugi S, Nagakura Y, Ogino S, Sekizawa T, Kiso M, Takahashi M, Ishikawa G, Ito H, and Shimizu Y.: *European Journal of Pain.* 2012, 16 (10): 1426-1436
- 5) Nagakura Y, Ito H, and Shimizu Y.: Animal models of fibromyalgia. In: *New insights into fibromyalgia* (eds Wike WS) pp41-58 InTech, Rijeka, 2012
- 6) Therapeutic potential of ASP3258, a selective phosphodiesterase 4 inhibitor, on chronic eosinophilic airway inflammation. Kobayashi M, Kubo S, Shiraki K, Iwata M, Hirano Y, Ohtsu Y, Takahashi K, and Shimizu Y.: *Pharmacology.* 2012, 90 (3-4): 223-232.
- 7) Kubo S, Kobayashi M, Iwata M, Miyata K, Takahashi K, and Shimizu Y.: Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor. *Int Immunopharmacol.* 2012, 12 (1): 59-63.

- 8) Kobayashi M, Kubo S, Hirano Y, Kobayashi S, Takahashi K, and Shimizu Y.: Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor. *Int Immunopharmacol.* 2012, 12 (1): 50-58.
- 9) Nagakura Y, Takahashi M, Noto T, Sekizawa T, Oe T, Yoshimi E, Tamaki K, and Shimizu Y.: Different pathophysiology underlying animal models of fibromyalgia and neuropathic pain: comparison of reserpine-induced myalgia and chronic constriction injury rats. *Behav Brain Res.* 2012, 226 (1): 242-249.
- 10) Katsumata K, Chono K, Sudo K, Shimizu Y, Kontani T, and Suzuki H.: Effect of ASP2151, a herpesvirus helicase-primase inhibitor, in a guinea pig model of genital herpes. *Molecules.* 2011, 16 (9): 7210-7223.
- 11) Kubo S, Kobayashi M, Iwata M, Takahashi K, Miyata K, and Shimizu Y.: Disease-modifying effect of ASP3258, a novel phosphodiesterase type 4 inhibitor, on subchronic cigarette smoke exposure-induced lung injury in guinea pigs. *Eur J Pharmacol.* 2011, 659 (1): 79-84
- 12) Takeshita N, Yoshimi E, Hatori C, Kumakura F, Seki N, and Shimizu Y.: Alleviating effects of AS1892802, a Rho kinase inhibitor, on osteoarthritic disorders in rodents. *J Pharmacol Sci.* 2011, 115 (4): 481-489.
- 13) Kobayashi M, Kubo S, Iwata M, Ohtsu Y, Takahashi K, and Shimizu Y.: ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. *Int Immunopharmacol.* 2011, 11 (6): 732-739.
- 14) Yoshimi E, Yamamoto H, Furuichi Y, Shimizu Y, and Takeshita N.: Sustained analgesic effect of the Rho kinase inhibitor AS1892802 in rat models of chronic pain. *J Pharmacol Sci.* 2010, 114 (1): 119-122.
- 15) Yoshimi E, Kumakura F, Hatori C, Hamachi E, Iwashita A, Ishii N, Terasawa T, Shimizu Y, and Takeshita N.: Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis. *J Pharmacol Exp Ther.* 2010, 334 (3): 955-963.
- 16) Chono K, Katsumata K, Kontani T, Kobayashi M, Sudo K, Yokota T, Konno K, Shimizu Y, and Suzuki H.: ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. *J Antimicrob Chemother.* 2010, 65 (8): 1733-1741
- 17) Kodama E, Orita M, Masuda N, Yamamoto O, Fujii M, Ohgami T, Kageyama S, Ohta M, Hatta T, Inoue H, Suzuki H, Sudo K, Shimizu Y, and Matsuoka M.: Binding modes of two

- novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase. *Antivir Chem Chemother.* 2008, 19 (3): 133-141.
- 18) Ohga K, Takezawa R, Arakida Y, Shimizu Y, and Ishikawa J.: Characterization of YM-58483/BTP2, a novel store-operated Ca²⁺ entry blocker, on T cell-mediated immune responses in vivo. *Int Immunopharmacol.* 2008, 8 (13-14): 1787-1792.
- 19) Ohga K, Kuromitsu S, Takezawa R, Numazaki M, Ishikawa J, Nagashima S, and Shimizu Y.: YM-341619 suppresses the differentiation of spleen T cells into Th2 cells in vitro, eosinophilia, and airway hyperresponsiveness in rat allergic models. *Eur J Pharmacol.* 2008, 590 (1-3): 409-416.
- 20) Ohga K, Takezawa R, Yoshino T, Yamada T, Shimizu Y, and Ishikawa J.: The suppressive effects of YM-58483/BTP-2, a store-operated Ca²⁺ entry blocker, on inflammatory mediator release in vitro and airway responses in vivo. *Pulm Pharmacol Ther.* 2008, 21 (2): 360-369
- 21) Saita Y, Kondo M, and Shimizu Y.: Species selectivity of small-molecular antagonists for the CCR5 chemokine receptor. *Int Immunopharmacol.* 2007, 7 (12): 1528-1534.
- 22) Masunaga Y, Noto T, Suzuki K, Takahashi K, Shimizu Y, and Morokata T.: Expression profiles of cytokines and chemokines in murine MDR1a^{-/-} colitis. *Inflammation Research* 2007, 56: 439-446
- 23) Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, and Shimizu Y.: A dual antagonist for chemokine CCR3 receptor and histamine H1 receptor. *Eur J Pharmacol.* 2007, 563 (1-3): 224-232.
- 24) Yamamoto S, Sugahara S, Ikeda K, and Shimizu Y.: Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059. *Eur J Pharmacol.* 2007, 559 (2-3): 219-226.
- 25) Yamamoto S, Sugahara S, Ikeda K, and Shimizu Y.: Pharmacological profile of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on acute and chronic inflammation models. *Eur J Pharmacol.* 2006, 550 (1-3): 166-172.
- 26) Saita Y, Kodama E, Orita M, Kondo M, Miyazaki T, Sudo K, Kajiwara K, Matsuoka M, and Shimizu Y.: Structural basis for the interaction of CCR5 with a small molecule, functionally selective CCR5 agonist. *J Immunol.* 2006, 177 (5): 3116-3122.
- 27) Yamamoto S, Sugahara S, Naito R, Ichikawa A, Ikeda K, Yamada T, and Shimizu Y.: The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on

- T-cell-related cytokine production in vitro and in vivo. *Eur J Pharmacol.* 2006, 541 (1-2): 106-114.
- 28) Suzuki K, Morokata T, Morihira K, Sato I, Takizawa S, Kaneko M, Takahashi K, and Shimizu Y.: In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. *Biochem Biophys Res Commun.* 2006, 339 (4): 1217-1223.
- 29) Morokata T, Suzuki K, Masunaga Y, Taguchi K, Morihira K, Sato I, Fujii M, Takizawa S, Torii Y, Yamamoto N, Kaneko M, Yamada T, Takahashi K, and Shimizu Y.: A novel, selective, and orally available antagonist for CC chemokine receptor 3. *J Pharmacol Exp Ther.* 2006, 317 (1): 244-250.
- 30) Kubo S, Kobayashi M, Masunaga Y, Ishii H, Hirano Y, Takahashi K, and Shimizu Y.: Cytokine and chemokine expression in cigarette smoke-induced lung injury in guinea pigs. *Eur Respir J.* 2005, 26 (6): 993-1001.
- 31) Sudo K, Yamaji K, Kawamura K, Nishijima T, Kojima N, Aibe K, Shimotohno K, and Shimizu Y.: High-throughput screening of low molecular weight NS3-NS4A protease inhibitors using a fluorescence resonance energy transfer substrate. *Antivir Chem Chemother.* 2005, 16 (6): 385-392.
- 32) Saita Y, Kondo M, Miyazaki T, Yamaji N, and Shimizu Y.: Transgenic mouse expressing human CCR5 as a model for in vivo assessments of human selective CCR5 antagonists. *Eur J Pharmacol.* 2005, 518 (2-3): 227-233.
- 33) Sudo K, Miyazaki Y, Kojima N, Kobayashi M, Suzuki H, Shintani M, and Shimizu Y.: YM-53403, a unique anti-respiratory syncytial virus agent with a novel mechanism of action. *Antiviral Res.* 2005, 65 (2): 125-131.
- 34) Masuda N, Yamamoto O, Fujii M, Ohgami T, Fujiyasu J, Kontani T, Moritomo A, Orita M, Kurihara H, Koga H, Kageyama S, Ohta M, Inoue H, Hatta T, Shintani M, Suzuki H, Sudo K, and Shimizu Y, Kodama E, Matsuoka M, Fujiwara M, Yokota T, Shigeta S, and Baba M.: Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. *Bioorg Med Chem.* 2005, 13 (4): 949-961.
- 35) Masuda N, Yamamoto O, Fujii M, Ohgami T, Fujiyasu J, Kontani T, Moritomo A, Orita M, Kurihara H, Koga H, Nakahara H, Kageyama S, Ohta M, Inoue H, Hatta T, Suzuki H, Sudo K, Shimizu Y, Kodama E, Matsuoka M, Fujiwara M, Yokota T, Shigeta S, and Baba M.: Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. *Bioorg Med Chem.* 2004, 12 (23): 6171-6182.

- 36) Inoue H, Sakashita H, Shimizu Y, Yamaji K, Yokota T, Sudo K, Shigeta S, and Shimotohno K.: Expression of a Hepatitis C Virus NS3 Protease-NS4A Fusion Protein in *Escherichia coli*. *Biochem Biophys Res Commun*. 1998, 245: 478-482
- 37) Watanabe K, Onoe T, Ozeki M, Shimizu Y, Sakayori T, Nakamura H, and Yoshimura F.: Sequence and Product Analyses of the Four Genes Downstream from the Fimbrilin Gene (FimA) of the Oral Anaerobe *Porphyromonas gingivalis*. *Microbiol Immunol*. 1996, 40: 725-734
- 38) Sudo K, Inoue H, Shimizu Y, Yamaji K, Konno K, Shigeta S, Kaneko T, Yokota T, Shimotohno K.: Establishment of an in vitro assay system for screening hepatitis C virus protease inhibitors using high performance liquid chromatography. *Antiviral Research* 1996, 32: 9-18
- 39) Hashiyama M, Iwama A, Ohshiro K, Kurozumi K, Yasunaga K, Shimizu Y, Masuho Y, Matsuda I, Yamaguchi N and Suda T.: Predominant Expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells. *Blood* 1996, 87: 93-101
- 40) Shimizu Y, Yamaji K, Masuho Y, Yokota T, Inoue H, Sudo K, Satoh S, and Shimotohno K.: Identification of the sequence on NS4A required for enhanced cleavage of the NS5A/5B site by Hepatitis C Virus NS3 protease. *J Virol*. 1996, 70: 127-132
- 41) Daniels RH, Elmore MA, Hill ME, Shimizu Y, Lacke JM, and Finnen MJ.: Priming of the oxidative burst in human neutrophils by physiological agonists or cytochalasin B results from the recruitment of previously non-responsive cells. *Immunology* 1994, 82: 465-472
- 42) Finan P, Shimizu Y, Gout I, Hsuan J, Troung O, Butcher C, Bennett P, Waterfield MD, and Kellie S.: An SH3 domain and protein-rich sequence mediate an interaction between two components of the phagocyte NADPH oxidase complex. *J Biol Chem*. 1994, 269: 13752-13755
- 43) Shimizu Y, Daniels RF, Elmore MA, Finnen MJ, Hill ME, and Lackie JM.: Agonist-stimulated Cl⁻ efflux from human neutrophils: a common phenomenon during neutrophil activation. *Biochemical Pharmacology* 1993, 45: 1743-1751
- 44) Shimizu Y, Takabayashi E, Yano S, Shimizu N, Yamada K and Gushima H.: Molecular cloning and expression in *E. coli* of the cDNA coding for rat lipocortin I (calpactin II). *Gene* 1988, 65: 141-147
- 45) Kudo S, Sugisaki M, Takanami T, Yamashita T, Ishino M, Shimizu Y, Ishida Y and Fujinaga K.: Structure of viral DNA in a rat cell line, GY1, transformed by adenovirus 12 Hind III fragment-G. *Virology* 1986, 148: 133-145

- 46) Fujinaga K, Yamashita T, Yoshida K, and Shimizu Y.: Organization, Integration, and transcription of transforming genes of oncogenic human adenovirus type 12 and 7. *Curr Top Microbiol Immunol.* 1984, 110: 53-72
- 47) Shimizu Y, Yoshida K, Ren CS, Fijinaga K, Rajagopalan S, and Chinnadurai G.: Hinf family: a novel repeated DNA family of the human genome. *Nature* 1983, 302: 587-590
- 48) **Shimizu Y**, Kumazaki T, and Ishii S.: Specific cleavage at fibers of a bacteriophage-tail-like bacteriocin, pyocin R1, by successive treatment with organomercurial compounds and trypsin. *J Virology* 1982, 44: 692-695
- 49) Fujinaga K, Yoshida K, Sawada Y, Kimura T and **Shimizu Y**.: Organization and expression of oncogenic human adenovirus transforming gene. In: Primary and tertiary structure of nucleic acids and cancer research (Eds. Miwa M) pp249-262 Japan Scientific Society Press, Tokyo 1982
- 50) Kimura T, Sawada Y, Shinagawa M, **Shimizu Y**, Shiroki K, Shimojo H, Sugisaki H, Takanami M, Uemizu Y, and Fujinaga K.: Nucleotide sequence of the transforming early region E1B of adenovirus type 12 DNA structure and gene organization and comparison with those of adenovirus type 5 DNA. *Nucleic Acids Res.* 1981, 9: 6571-6589